Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > ULURU Inc. Announces Filing of OraDisc(TM) B Regulatory Dossier in Europe

Abstract:
ULURU Inc. today announced that Meldex International PLC (previously BioProgress PLC) has filed the regulatory dossier for approval of ULURU's proprietary product OraDisc(TM) B in Europe.

ULURU Inc. Announces Filing of OraDisc(TM) B Regulatory Dossier in Europe

ADDISON, TX | Posted on December 19th, 2007

OraDisc(TM) B is a product developed from our adhesive film technology which incorporates 15 milligrams of benzocaine for the treatment of oral pain. The product is designed to adhere to the mucosal surface and selectively deliver pain relief to a localized area. Compared with currently marketed gel products, OraDisc(TM) B provides a significantly greater period of pain relief as the adhesive film is designed to erode over a 1 - 1.5 hour period.

Under the terms of the agreement this will trigger a major milestone payment from Meldex International PLC in February 2008 which was payable on the later to occur of the registration filing or the first anniversary of the signing of the agreement.

Commenting on the registration filing, Kerry P. Gray, President and Chief Executive Officer of ULURU, stated "I am very pleased with the progress Meldex has made preparing and submitting the OraDisc(TM) B Dossier. Securing a regulatory approval for our adhesive film technology in Europe is an important step in our overall commercialization strategy for this technology."

Steve Martin, Chief Development Officer of Meldex International PLC, added "Strategically this is an important product in our portfolio as it compliments our existing range of products in supportive care and pain management and our instant release Soluleaves(TM) technology. Given our expanding European presence this novel product offers us the potential to build a significant presence in the pain management market."

####

About ULURU Inc.
ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology.

About Meldex International PLC:

Meldex International is a specialty pharmaceutical and healthcare product business that uses its XGEL(TM) polymer technologies to develop and enhance medicines and OTC products.

Meldex International possesses an array of innovative enabling systems which are applied to enhance its own pharmaceutical and healthcare products and those of its partners. The Company has product development agreements and strategic alliances with several global pharmaceuticals companies including Barr Pliva and FMC BioPolymer Inc.

Meldex is an international operation. It has sales and marketing infrastructure in the UK, Austria, Germany, France, Italy and the USA; distribution agreements covering Canada, South America, the CEE region, Asia the Far East and other territories, product development in the UK and USA and a product portfolio of branded and generic pharmaceutical and healthcare products across the globe.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the registration of our adhesive film technology in Europe, the product advantages of OraDisc(TM) B and the potential to establish a significant presence in the pain management market. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, Quarterly report Form 10-QSB for the quarter ended September 30, 2007 and other reports filed by us with the Securities and Exchange Commission.

For more information, please click here

Contacts:
Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Govt.-Legislation/Regulation/Funding/Policy

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Researchers’ approach may protect quantum computers from attacks March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Optically trapped quantum droplets of light can bind together to form macroscopic complexes March 8th, 2024

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project